There are several determinants that could have an effect on in-licensing decisions by a pharmaceutical or biotech firm. This work studies over 200 licensing deals involving big pharma companies in the period (2011 – 2015) and identifies different factors that could play a role in licensing...

The global pharmaceutical industry is in an era of greater uncertainty because of looming patent expiries of established drugs having a direct impact on their sales and profitability. Further discovering new drugs in-house is a risky, time consuming and expensive proposition. This has forced...

The drug discovery and development are very expensive, risky and time consuming. It requires several years and billions of dollars for developing a drug to the marketplace. Hence, smaller biotech companies seek to out-license or develop their drugs in collaboration with large pharmaceutical...